2025
Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis
Sannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A, Al-Bawardy B. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848241312766. PMID: 39802627, PMCID: PMC11719443, DOI: 10.1177/17562848241312766.Peer-Reviewed Original ResearchOral vancomycin therapyPrimary sclerosing cholangitisIBD-PSCInflammatory bowel diseasePooled analysisClinical responseSclerosing cholangitisEpisodes of acute cholangitisFavorable side effect profilePooled analysis of studiesSystematic reviewInflammatory bowel disease associated with primary sclerosing cholangitisSide effect profileLong-term safetyClinical response/remissionVancomycin therapyOral vancomycinClinical remissionEndoscopic remissionAcute cholangitisMedian durationImmunosuppressive agentsNo episodesConcomitant treatmentEffect profileAuthors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.
Al-Bawardy B, Quraishi M. Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848251328606. PMID: 40144790, PMCID: PMC11938434, DOI: 10.1177/17562848251328606.Peer-Reviewed Original Research
2021
Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials
Assis DN, Levy C. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. Hepatology 2021, 73: 887-889. PMID: 33403699, DOI: 10.1002/hep.31702.Peer-Reviewed Original Research
2020
Laboratory Testing, Diagnostic Coding, and Treatment for Electronic Identification of Clostridioides difficile Infection
Stevens V, Benin A, Dantes R, Khader K, Nugent S, Lewis J, Adam T, Zhang R, Fu S, Jones M, Pollock D, Waisbren S. Laboratory Testing, Diagnostic Coding, and Treatment for Electronic Identification of Clostridioides difficile Infection. Infection Control And Hospital Epidemiology 2020, 41: s309-s309. DOI: 10.1017/ice.2020.897.Peer-Reviewed Original ResearchClostridioides difficile infectionPositive laboratory testsOral vancomycinICD codesPositive testElectronic health recordsCDI eventsDifficile infectionDiagnostic codingVeterans Affairs Health SystemHealth recordsProportion of patientsICD-10-CM codesPrior positive testLaboratory testsLong-term carePossibility of treatmentAccompanying treatmentInpatient courseDifficile testingRetrospective cohortTreatment initiationNinth RevisionRecurrent episodesDiagnosis codes
1996
Albendazole-induced pseudomembranous colitis.
Shah V, Marino C, Altice FL. Albendazole-induced pseudomembranous colitis. The American Journal Of Gastroenterology 1996, 91: 1453-4. PMID: 8678015.Peer-Reviewed Original ResearchConceptsPseudomembranous colitisIntestinal microsporidiosisDifficile toxinPositive stool specimenC. difficile toxinClostridium difficile toxinAbdominal painOral vancomycinFlexible sigmoidoscopyPatient's symptomsCase reportStool specimenPathogenic mechanismsColitisAlbendazolePatientsSymptomsMetronidazoleAIDSMicrosporidiosisTreatmentToxinSigmoidoscopyPainDiarrhea
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply